Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2821636 | 0.90 | GAA (0.36) | MMP13TNKSPARP1TNKS2GAA | |
| SCHEMBL2821942 | 0.88 | EGFR (0.33) | MMP13TNKSPARP1TNKS2GAA | |
| SCHEMBL2821739 | 0.86 | TSHR (0.34) | MMP13TNKSPARP1TNKS2KDM4E | |
| SCHEMBL2823051 | 0.86 | MMP13 (0.34) | MMP13TNKSPARP1TNKS2GAA | |
| SCHEMBL23652954 | 0.86 | MEN1 (0.34) | MMP13TNKSPARP1TNKS2GAA | |
| SCHEMBL2820566 | 0.86 | MMP13 (0.32) | MMP13TNKSPARP1TNKS2GAA | |
| SCHEMBL2851123 | 0.84 | KDM4E (0.34) | MMP13TNKSPARP1TNKS2GAA | |
| SCHEMBL2822078 | 0.84 | MMP13 (0.37) | MMP13TNKSPARP1TNKS2GAA | |
| SCHEMBL2821567 | 0.83 | MMP13 (0.33) | MMP13TNKSPARP1TNKS2GAA | |
| SCHEMBL23652699 | 0.83 | MMP13 (0.35) | MMP13TNKSPARP1TNKS2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1386914-B1 | HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS | MEIJI SEIKA KAISHA (JP) | 2010-10-27 | — | — | EP | claimed |
| US-7022855-B2 | Halogen-substituted quinoline derivatives and ectoparasite control agent | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-04 | — | — | US | claimed |
| EP-1559321-A1 | MIXED COMPOSITIONS FOR CONTROLLING PARASITIC INSECTS | MEIJI SEIKA KAISHA LTD. (JP) | 2005-08-03 | — | — | EP | claimed |
| US-20040087618-A1 | Halogen-substituted quinoline derivatives and ectoparasite control agent | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-05-06 | — | — | US | claimed |
| US-20040077602-A1 | Mixture composition for controlling ectoparasites | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-04-22 | — | — | US | claimed |
| EP-1386914-A1 | HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS | MEIJI SEIKA KAISHA LTD. (JP) | 2004-02-04 | — | — | EP | claimed |
| EP-1386914-B1 | HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS | MEIJI SEIKA KAISHA (JP) | 2010-10-27 | — | — | EP | disclosed |
| US-7022855-B2 | Halogen-substituted quinoline derivatives and ectoparasite control agent | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1559321-A1 | MIXED COMPOSITIONS FOR CONTROLLING PARASITIC INSECTS | MEIJI SEIKA KAISHA LTD. (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-20040087618-A1 | Halogen-substituted quinoline derivatives and ectoparasite control agent | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-05-06 | — | — | US | disclosed |
| US-20040077602-A1 | Mixture composition for controlling ectoparasites | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1386914-A1 | HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS | MEIJI SEIKA KAISHA LTD. (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087618-A1 | Halogen-substituted quinoline derivatives and ectoparasite control agent | ATL3, RABL3, RAB5C | MMP13 3596/4885TNKS 4821/4885PARP1 4019/4885 |
| US-20040077602-A1 | Mixture composition for controlling ectoparasites | SF3A3, PEX3, HCN3 | MMP13 2183/4885TNKS 4868/4885PARP1 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.